JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced it will present preclinical data on the company's novel oral C5aR inhibitor, INF904, at the 2024 European Meeting on Complement in Human Diseases (EMCHD) being held in Lübeck, Germany, September 2 – 6, 2024. In addition to two poster presentations, InflaRx representatives will participate in a C5a/C5aR-focused pan ...

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- SL Green Realty Corp. (NYSE:SLG), Manhattan's largest office landlord, today announced that, together with its joint venture partner, it has closed on a modification and extension of the mortgage on 220 East 42nd Street. The modification included a paydown of the principal balance by $9.0 million to $496.4 million and extended the maturity date by more than three years from July 2024 to December 2027. The interest rate was maintained at 2.75% over term SOFR, which ...

文章核心观点 - 公司推出HotelHelp项目,为人口拐卖受害者提供短期紧急住宿 [2][3][4] - 该项目目前在5个美国城市试点,未来计划扩展到25个北美城市,并逐步在全球范围内推广 [3] - 该项目旨在解决人口拐卖受害者缺乏专门庇护所的问题,减少他们再次被拐卖的风险 [4] - 该项目借鉴了HospitalityHelps为乌克兰难民提供短期酒店住宿的成功经验 [5] 公司概况 - 公司是一家全球性酒店集团,拥有近8,900家酒店,遍布141个国家和地区 [10] - 公司旗下拥有30多个知名品牌,并运营Marriott Bonvoy旅程奖励计划 [10][11] 反人口拐卖和员工培训 - 公司自2016年起为所有酒店员工提供人口拐卖识别和应对培训,已有超过130万名员工接受培训 [8] - 公司还将该培训模块捐赠给行业,已有超过160万人次完成培训 [8] - 公司正在努力将该培训推广到全球酒店业 [8] 其他相关举措 - 公司与马里兰大学SAFE中心合作,推出针对人口拐卖受害者的"未来培训"职业培训课程 [7] - 公司和马里奥特基金会共同向AHLA基金会捐赠55万美元,用于支持前线救助组织 [7]

DETROIT, July 30, 2024 (GLOBE NEWSWIRE) -- DT Midstream, Inc. (NYSE:DTM) today announced second quarter 2024 reported net income of $96 million, or $0.98 per diluted share. For the second quarter of 2024, Operating Earnings were also $96 million, or $0.98 per diluted share. Adjusted EBITDA for the quarter was $248 million. Reconciliations of Operating Earnings and Adjusted EBITDA (non-GAAP measures) to reported net income are included at the end of this news release. The company also announced that the DT M ...

ANAVEX®2-73 corrects directly to humans' translatable EEG biomarkers in a model of Fragile X Syndrome (FXS) Therapeutic potential to address behavioral and cognitive deficits in individuals with neurodevelopmental disorders Plans advancing to initiate a clinical trial in individuals with FXS NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Al ...

Continued Customer Adoption of Industry-Leading Technologies Helps Drive Share Gains; Debt-Free Balance Sheet Supports Long-Term Investment and Growth MIAMI, July 30, 2024 (GLOBE NEWSWIRE) -- Watsco, Inc. (NYSE:WSO) announced its operating results for the second quarter and six-month period ended June 30, 2024. Commentary was also provided on business trends, growth opportunities, technology innovation and its financial position. Watsco is the largest distributor in the highly fragmented $64 billion North A ...

SOL-R evaluates repeat AXPAXLI™ dosing for wet age-related macular degeneration (wet AMD) Global non-inferiority study comparing AXPAXLI, dosed every six months, to 2 mg aflibercept every eight weeks BEDFORD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, t ...

Achieved $8.2 million in OJEMDATM (tovorafenib) net product revenues in initial 2 months of launch Expanded pipeline with DAY301, potential first-in-class Antibody Drug Conjugate (ADC) targeting PTK7 Entered into exclusive licensing agreement with Ipsen to commercialize tovorafenib outside of the U.S. for approximately $111 million upfront in cash and equity investment at a premium Entered into a definitive agreement for an oversubscribed private placement of its securities for total gross proceeds of appro ...

文章核心观点 - 生物创新公司Bioventus将于2024年8月6日发布2024财年第二季度财报 [1] - 公司将于当天上午8:30举行电话会议,讨论财报结果并提供业务更新 [1] - 公司通过网络直播和相关材料在其投资者关系网站上提供会议信息 [2] - Bioventus是一家专注于创新活跃疗愈产品的全球领先公司,其产品涵盖疼痛治疗、修复疗法和手术解决方案 [3] - 公司以高质量标准、循证医学和强大的道德行为为基础,是全球医生的可信伙伴 [3] 公司概况 - Bioventus是一家专注于创新活跃疗愈产品的全球领先公司 [3] - 公司的产品涵盖疼痛治疗、修复疗法和手术解决方案 [3] - 公司以高质量标准、循证医学和强大的道德行为为基础,是全球医生的可信伙伴 [3] 财务信息 - Bioventus将于2024年8月6日发布2024财年第二季度财报 [1] - 公司将于当天上午8:30举行电话会议,讨论财报结果并提供业务更新 [1]

NEW YORK, July 30, 2024 /PRNewswire/ -- S&P Global (NYSE: SPGI) today reported second quarter 2024 results. The Company's earnings release and supplemental materials are available at http://investor.spglobal.com/Quarterly-Earnings. Supplemental Information/Conference Call/Webcast Details:  The Company's senior management will review the second quarter 2024 earnings results on a conference call scheduled for today, July 30, at 8:30 a.m. EDT. Additional information presented on the conference call may be foun ...